Cardiol Therapeutics develops innovative cannabidiol medicines for heart disease.
Cardiol Therapeutics has raised $7.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in September 2026.
Cardiol Therapeutics's investors include Raymond James, Canaccord Genuity Group, AlbaCore Capital, Echelon Wealth Partners.
Cardiol Therapeutics is headquartered in Oakville, Canada.
Cardiol Therapeutics develops innovative cannabidiol medicines for heart disease.
Cardiol Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cardiol Therapeutics — Funding & Investors." VCBacked, September 16, 2026, https://www.vcbacked.co/company/cardiol-therapeutics. Accessed November 14, 2026.
VCBacked. (2026). Cardiol Therapeutics — Funding & Investors. Retrieved November 14, 2026, from https://www.vcbacked.co/company/cardiol-therapeutics
{{cite web |title=Cardiol Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/cardiol-therapeutics |website=VCBacked |access-date=November 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Cardiol Therapeutics? Request a listing update